Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortization of Deferred Charges (2019 - 2022)

Historic Amortization of Deferred Charges for Viking Therapeutics (VKTX) over the last 4 years, with Q1 2022 value amounting to $77000.0.

  • Viking Therapeutics' Amortization of Deferred Charges rose 694.44% to $77000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $301000.0, marking a year-over-year increase of 711.74%. This contributed to the annual value of $296000.0 for FY2021, which is 685.92% up from last year.
  • Per Viking Therapeutics' latest filing, its Amortization of Deferred Charges stood at $77000.0 for Q1 2022, which was up 694.44% from $76000.0 recorded in Q4 2021.
  • Viking Therapeutics' Amortization of Deferred Charges' 5-year high stood at $77000.0 during Q1 2022, with a 5-year trough of $64000.0 in Q1 2019.
  • Its 4-year average for Amortization of Deferred Charges is $70000.0, with a median of $70000.0 in 2020.
  • As far as peak fluctuations go, Viking Therapeutics' Amortization of Deferred Charges skyrocketed by 757.58% in 2020, and later skyrocketed by 588.24% in 2021.
  • Quarter analysis of 4 years shows Viking Therapeutics' Amortization of Deferred Charges stood at $66000.0 in 2019, then rose by 7.58% to $71000.0 in 2020, then grew by 7.04% to $76000.0 in 2021, then increased by 1.32% to $77000.0 in 2022.
  • Its Amortization of Deferred Charges was $77000.0 in Q1 2022, compared to $76000.0 in Q4 2021 and $75000.0 in Q3 2021.